A study of Irish primary-care dispensing found falling benzodiazepine and Z-drug rates from 2014 to 2022. Its comparison with England needs qualification because the underlying populations differed.
Mattsson and colleagues analyzed monthly dispensing through Ireland’s means-tested General Medical Services scheme. The reported combined rate fell from 1,531 to 1,474 dispensings per thousand eligible people. High-risk patterns also declined on several measures.
England’s reported rate declined more steeply, from 288 to 210 per thousand. These are dispensing counts per population, not percentages of individuals taking medication; a person can contribute more than one dispensing.
The Irish scheme’s eligibility structure differed from the NHS population used for comparison. Deprivation subgroup analysis could not fully address age differences. The investigators also lacked indications, adherence, complete hospitalization time, and eligibility-start or end dates.
Dispensing of other sedating agents could reflect indications unrelated to sleep. A shift in drug-class totals therefore cannot by itself demonstrate substitution for insomnia treatment.
Use the study to discuss prescribing-system patterns, with its denominator and time period explicit. It cannot establish consumption, concentration, impairment, or inappropriate prescribing in an individual. A national difference also does not identify which policy or clinician behavior caused the observed gap.
Original analysis of the supplied journal article, identified as PMC12541714.